Revolution Medicines, Inc.RVMDNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 95% recommend buying.

Consensus Rating

Buy

20 analysts·High coverage

95%

Rating Distribution

Strong Buy

15%

Buy

1890%

Hold

15%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see moderate upside — consensus target 19% higher.

Bear Case

$73.00

-26%

Consensus

$116.50

+19%

Bull Case

$170.00

+73%

Price Range20 analysts

Low

Consensus

High

$73.00

$170.00

Current Target

Current Price

$98.25

Upside to Target

$18.25

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-6.60(15 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+747.51%

EPS—

FY2028

Rev+220.42%

EPS—

FY2029

Rev+109.53%

EPS—

Earnings Surprises

Beat rate:33%(4/12 quarters)

Avg surprise:-5.9%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 27, 2026Oppenheimer

Revolution Medicines price target raised to $150 from $75 at Oppenheimer

Target:$150.00

+53.4%from $97.78

Jan 22, 2026UBS

Revolution Medicines price target raised to $170 from $85 at Stifel

Target:$170.00

+44.3%from $117.84

Jan 21, 2026RBC Capital

Revolution Medicines price target raised to $140 from $77 at RBC Capital

Target:$140.00

+20.5%from $116.22

Jan 20, 2026Guggenheim

Revolution Medicines price target raised to $160 from $92 at Guggenheim

Target:$160.00

+33.0%from $120.28

Jan 13, 2026Goldman Sachs

Goldman Sachs on Revolution (RVMD): 'Catalyst-rich 2026 underpins the breadth of the clinical portfolio'

Target:$73.00

-39.1%from $119.95

Jan 13, 2026Mizuho Securities

Revolution Medicines price target raised to $143 from $90 at Mizuho

Target:$143.00

+22.0%from $117.17

Jan 9, 2026Wedbush

Revolution Medicines price target raised to $147 from $80 at Wedbush

Target:$147.00

+30.5%from $112.68

Nov 3, 2025RBC Capital

RBC Capital Starts Revolution (RVMD) at Outperform

Target:$77.00

+30.9%from $58.84

Oct 17, 2025National Bank

Revolution Medicines price target raised to $80 from $78 at BofA

Target:$80.00

+48.7%from $53.81

Oct 17, 2025Raymond James

Revolution Medicines price target raised to $76 from $72 at Raymond James

Target:$76.00

+53.0%from $49.68

Oct 15, 2025Stifel Nicolaus

Revolution Medicines resumed with a Buy at Stifel

Target:$85.00

+71.5%from $49.56

Sep 5, 2025Truist Financial

Revolution Medicines initiated with a Buy at Truist

Target:$99.00

+144.4%from $40.50

Aug 19, 2025Piper Sandler

Piper starts Revolution Medicines at Overweight on daraxonrasib potential

Target:$75.00

+105.1%from $36.56

May 14, 2025H.C. Wainwright

Revolution Medicines price target lowered to $72 from $73 at H.C. Wainwright

Target:$72.00

+71.9%from $41.88

Apr 1, 2025Stifel Nicolaus

Revolution Medicines price target lowered to $64 from $78 at Stifel

Target:$64.00

+90.4%from $33.62

Jan 8, 2025UBS

Revolution Medicines price target raised to $71 from $65 at UBS

Target:$71.00

+60.2%from $44.33

Nov 7, 2024Piper Sandler

Revolution (RVMD) PT Raised to $70 at Piper Sandler

Target:$70.00

+24.8%from $56.09

Nov 4, 2024H.C. Wainwright

Revolution (RVMD) PT Raised to $62 at H.C. Wainwright

Target:$62.00

+11.0%from $55.87

Oct 28, 2024Guggenheim

Revolution Medicines price target raised to $82 from $72 at Guggenheim

Target:$82.00

+74.6%from $46.96

Oct 28, 2024Oppenheimer

Revolution (RVMD) PT Raised to $60 at Oppenheimer

Target:$60.00

+28.1%from $46.83

Oct 15, 2024Oppenheimer

Oppenheimer Reiterates Outperform Rating on Revolution (RVMD)

Target:$55.00

+11.7%from $49.22

Sep 17, 2024Piper Sandler

Piper Sandler Reiterates Overweight Rating on Revolution (RVMD)

Target:$57.00

+28.8%from $44.24

Aug 8, 2024Needham

Revolution (RVMD) PT Lowered to $61 at Needham

Target:$61.00

+42.8%from $42.73

Jul 15, 2024Wedbush

Revolution Medicines price target raised to $59 from $46 at Wedbush

Target:$59.00

+25.5%from $47.01

Apr 19, 2024Stifel Nicolaus

Revolution (RVMD) PT Raised to $43 at Stifel

Target:$43.00

+20.0%from $35.83

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance